Compare
AVITA Medical, Inc. vs Sight Sciences, Inc. vs PRO DEX Inc vs TELA Bio, Inc.
| Latest fiscal year | AVITA Medical, Inc. RCEL | Sight Sciences, Inc. SGHT | PRO DEX Inc PDEX | TELA Bio, Inc. TELA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $71.61M | $77.36M | $77.55M | $80.28M |
| Revenue growth (YoY) | +11.5% | -3.1% | +16.5% | +15.8% |
| Gross margin | 82.1% | 86.2% | 31.4% | 67.7% |
| Operating margin | -59.4% | -48.0% | 16.8% | -42.0% |
| Net margin | -67.8% | -49.7% | 17.6% | -48.4% |
| Net income | -$48.59M | -$38.43M | $13.66M | -$38.83M |
| EPS (Diluted) | -$1.74 | -$0.74 | $4.12 | -$0.83 |
| Operating cash flow | -$31.20M | -$29.69M | $7.24M | -$28.22M |
| Free cash flow | -$32.20M | -$29.92M | $6.76M | -$28.67M |
| Cash & equivalents | $10.24M | $91.97M | $8.19M | $50.84M |
| Total assets | $56.39M | $115.30M | $74.51M | $81.42M |
| Total liabilities | $73.04M | $51.36M | $26.88M | $75.11M |
| Shareholders' equity | -$16.65M | $63.94M | $47.63M | $6.31M |
| Return on year-end equity | n/a | -60.1% | 28.7% | -615.1% |
| Shares outstanding | 30.57M | 53.49M | 3.19M | 44.54M |
Revenue, most recent five fiscal years
| Fiscal year | AVITA Medical, Inc. | Sight Sciences, Inc. | PRO DEX Inc | TELA Bio, Inc. |
|---|---|---|---|---|
| Latest | $71.61M Ended 2025-12-31 | $77.36M Ended 2025-12-31 | $77.55M Ended 2026-06-30 | $80.28M Ended 2025-12-31 |
| 1 year earlier | $64.25M Ended 2024-12-31 | $79.87M Ended 2024-12-31 | $66.59M Ended 2025-06-30 | $69.30M Ended 2024-12-31 |
| 2 years earlier | $50.14M Ended 2023-12-31 | $81.06M Ended 2023-12-31 | $53.84M Ended 2024-06-30 | $58.45M Ended 2023-12-31 |
| 3 years earlier | $34.42M Ended 2022-12-31 | $71.33M Ended 2022-12-31 | $46.09M Ended 2023-06-30 | $41.42M Ended 2022-12-31 |
| 4 years earlier | n/a | $48.96M Ended 2021-12-31 | $42.04M Ended 2022-06-30 | $29.46M Ended 2021-12-31 |